Skip to main content Skip to search Skip to main navigation

EMA: New Q&A on Third Party Audits in the QP Declaration

EMA has published a Q&A on how to reflect third party audit(s) in part C of the QP declaration.

In part C of the QP declaration, information on audits as basis of QP Declaration of GMP Compliance should be given. Audit(s) of the active substance manufactured at the site(s) listed in PART A should be reported.

The Q&A includes a table where the manufacturing/import authorisation holder (MIAH) site (contract giver) and the audit body (contract acceptor) must be listed.

If the audit is undertaken by the MIAH, the auditing body column should be left empty. If the audit is performed by a third-party body (i.e. contract acceptor on behalf of the MIAH contract giver), this should be detailed as reflected in the contract.

In case the audit is performed on behalf of the MIAH by different entity/entities belonging to the same overall company, this should also be detailed in the auditing body column.

It is emphasised that in case the MIAH site does not perform the audit itself, the MIAH should be the contract giver. Consequently, the contract giver should always correspond to the MIAH site and the contract acceptor is expected to be the auditing body that actually performed the audit.


Source:

EMA: Questions and answers on how should third party audit(s) be reflected in part C of the QP declaration?


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

What is a gas?

What is a gas?

You can view the answer here:
Read more
EMA: Pilot Programme for Breakthrough Devices

EMA: Pilot Programme for Breakthrough Devices

The EMA plans to launch a pilot programme in Q2 2026 to implement the guidance for breakthrough devices issued in December 2025.

Read more
EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

The European Pharmacopoeia (Ph. Eur.) has introduced a new general chapter that provides a framework for managing the quality of data, including digital data, throughout its life cycle.

Read more
PIC/S: Jordan FDA Joins PIC/S

PIC/S: Jordan FDA Joins PIC/S

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

Read more
Swissmedic: Scientific GMDP Meetings

Swissmedic: Scientific GMDP Meetings

Swissmedic offers companies holding or seeking a Swissmedic manufacturing or distribution license the opportunity to discuss project-specific GMP and GDP topics in Scientific GMDP Meetings.

Read more
Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

A new Chinese Pharmacopoeia was published in 2025. This has some significant implications for the pharmaceutical water industry, which we will discuss in more detail in this article. Firstly, it is important to note that cold WFI systems are now permitted worldwide and can be used across the board.
Read more
Previous
Next